Page last updated: 2024-09-04
pralnacasan and docetaxel
pralnacasan has been researched along with docetaxel in 1 studies
Compound Research Comparison
Studies (pralnacasan) | Trials (pralnacasan) | Recent Studies (post-2010) (pralnacasan) | Studies (docetaxel) | Trials (docetaxel) | Recent Studies (post-2010) (docetaxel) |
---|---|---|---|---|---|
19 | 0 | 7 | 101 | 0 | 33 |
Protein Interaction Comparison
Protein | Taxonomy | pralnacasan (IC50) | docetaxel (IC50) |
---|---|---|---|
Tubulin beta-4A chain | Homo sapiens (human) | 0.5 | |
Tubulin beta chain | Homo sapiens (human) | 0.5 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
Tubulin alpha-3C chain | Homo sapiens (human) | 0.5 | |
Substance-K receptor | Homo sapiens (human) | 1.563 | |
Tubulin alpha-1B chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-4A chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-4B chain | Homo sapiens (human) | 0.5 | |
Growth hormone-releasing hormone receptor | Homo sapiens (human) | 0.0001 | |
Tubulin beta-3 chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-2A chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-8 chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-3E chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-1A chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-1C chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-6 chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-2B chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-1 chain | Homo sapiens (human) | 0.5 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Other Studies
1 other study(ies) available for pralnacasan and docetaxel
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |